Advances in the field of boron chemistry have expanded the application of boron from material use to medicine. Boron-based drugs represent a new class of molecules that possess several biomedical applications including use as imaging agents for both optical and nuclear imaging as well as therapeutic agents with anticancer, antiviral, antibacterial, antifungal and other disease-specific activities. For example, bortezomib (Velcade(®)), the only drug in clinical use with boron as an active element, was approved in 2003 as a proteasome inhibitor for the treatment of multiple myeloma and non-Hodgkin's lymphoma. Several other boron-based compounds are in various phases of clinical trials, which illustrates the promise of this approach for medicinal chemists working in the area of boron chemistry. It is expected that in the near future, several boron-containing drugs should become available in the market with better efficacy and potency than existing drugs. This article discusses the current status of the development of boron-based compounds as diagnostic and therapeutic agents in humans.
Advances in the field of boron chemistry have expanded the application of n class="Chemical">boron from material use to medicine. Boron-based drugs represent a new class of molecules that possess several biomedical applications including use as imaging agents for both optical and nuclear imaging as well as therapeutic agents with anticancer, antiviral, antibacterial, antifungal and other disease-specific activities. For example, bortezomib (Velcade(®)), the only drug in clinical use with boron as an active element, was approved in 2003 as a proteasome inhibitor for the treatment of multiple myeloma and non-Hodgkin's lymphoma. Several other boron-based compounds are in various phases of clinical trials, which illustrates the promise of this approach for medicinal chemists working in the area of boron chemistry. It is expected that in the near future, several boron-containing drugs should become available in the market with better efficacy and potency than existing drugs. This article discusses the current status of the development of boron-based compounds as diagnostic and therapeutic agents in humans.
Authors: Morten M Smedskjaer; John C Mauro; Randall E Youngman; Carrie L Hogue; Marcel Potuzak; Yuanzheng Yue Journal: J Phys Chem B Date: 2011-10-18 Impact factor: 2.991
Authors: Ulrich auf dem Keller; Caroline L Bellac; Ying Li; Yuanmei Lou; Philipp F Lange; Richard Ting; Curtis Harwig; Reinhild Kappelhoff; Shoukat Dedhar; Michael J Adam; Thomas J Ruth; François Bénard; David M Perrin; Christopher M Overall Journal: Cancer Res Date: 2010-08-20 Impact factor: 12.701
Authors: Sherifa Hasabelnaby; Ayman Goudah; Hitesh K Agarwal; Mosaad S M abd Alla; Werner Tjarks Journal: Eur J Med Chem Date: 2012-07-27 Impact factor: 6.514
Authors: Andrea Sartore-Bianchi; Fabio Gasparri; Arturo Galvani; Linda Nici; James W Darnowski; Dario Barbone; Dean A Fennell; Giovanni Gaudino; Camillo Porta; Luciano Mutti Journal: Clin Cancer Res Date: 2007-10-01 Impact factor: 12.531
Authors: Simona Zuppolini; Giuseppe Quero; Marco Consales; Laura Diodato; Patrizio Vaiano; Alberto Venturelli; Matteo Santucci; Francesca Spyrakis; Maria P Costi; Michele Giordano; Antonello Cutolo; Andrea Cusano; Anna Borriello Journal: Biomed Opt Express Date: 2017-10-23 Impact factor: 3.732
Authors: Robson Xavier Faria; Noemi de Jesus Hiller; Juliana Pimenta Salles; Jackson Antonio Lamounier Camargos Resende; Roberta Tosta Diogo; Natalia Lidmar von Ranke; Murilo Lamim Bello; Carlos Rangel Rodrigues; Helena Carla Castro; Daniela de Luna Martins Journal: J Bioenerg Biomembr Date: 2019-06-29 Impact factor: 2.945